AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral inpatient treatment (n = 130)
Number of subjects: 267
Study 17053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic inpatient treatment (n = 137)
Number of subjects: 267
Study 17053334 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 267
Study 12753351 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal noxious stimulus during SWS
Number of subjects: 10
Study 12753351 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal noxious stimulus during REM sleep
Number of subjects: 10
Study 12753351 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal noxious stimulus when awake
Number of subjects: 10
Study 12753351 — intervention group
Group type: COMPARATOR
Intervention: Time-of-night effect on pain perception
Number of subjects: 10
Study 10689256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1259
Study 9496173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clerking by a specialist nurse using a standard proforma and ordering pre-operative investigations
Number of subjects: 100
Study 9496173 — intervention group
Group type: COMPARATOR
Intervention: Clerking by PRHOs who ordered investigations as is their normal practice
Number of subjects: 100
Study 9496173 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse's performance in limited physical examination, ordering investigations, and assessing ASA grades
Number of subjects: 100
Study 7678870 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 1645
Study 7678870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study 3315923 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 121
Study 3315923 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 121
Study 3315923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 121
Study 3315923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 121
Study 30041603 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Planning (IP) intervention
Number of subjects: 400
Study 30041603 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Planning (CP) intervention
Number of subjects: 400
Study 30041603 — intervention group
Group type: COMPARATOR
Intervention: No-planning control condition 1
Number of subjects: 400
Study 30041603 — intervention group
Group type: COMPARATOR
Intervention: No-planning control condition 2
Number of subjects: 400
Study 27745816 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR‐V (50%)
Number of subjects: 35
Study 27745816 — intervention group
Group type: COMPARATOR
Intervention: ASIR (30%, 50%, and 70%)
Number of subjects: 35
Study 27745816 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR‐V (70%)
Number of subjects: 35
Study 22377275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum assisted closure (VAC®)
Number of subjects: 50
Study 22377275 — intervention group
Group type: COMPARATOR
Intervention: Shoelace technique
Number of subjects: 50
Study 21447749 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of two lessons, an Internet site, and sexual health services at school sites.
Number of subjects: 0
Study 21447749 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods derived from social cognitive theory, elaboration likelihood model, persuasive communication matrix, and theories about risk communication.
Number of subjects: 0
Study 20818875 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care integrated with standard oncologic care
Number of subjects: 151
Study 20818875 — intervention group
Group type: COMPARATOR
Intervention: Standard oncologic care alone
Number of subjects: 151
Study 18061416 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (3 cans daily, 40 g ethanol)
Number of subjects: 20
Study 16172182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 28
Study 16172182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12881376 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular invitation to screening (ASP)
Number of subjects: 77080
Study 12881376 — intervention group
Group type: COMPARATOR
Intervention: No invitation to screening (PSP)
Number of subjects: 77080
Study 10516931 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin once-a-day therapy (200 mg/day for 7 days)
Number of subjects: 90
Study 10516931 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin twice-a-day therapy (200 mg/day for 7 days)
Number of subjects: 90
Study 9032009 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐Layer Perceptron (MLP) classifier
Number of subjects: 0
Study 9032009 — intervention group
Group type: COMPARATOR
Intervention: Bayes classifier
Number of subjects: 0
Study 9032009 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network based classifiers
Number of subjects: 0
Study 9032009 — intervention group
Group type: COMPARATOR
Intervention: Human experts
Number of subjects: 0
Study 1564134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 17
Study 1564134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2865177 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and metronidazole
Number of subjects: 146
Study 2865177 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G/amoxicillin and metronidazole
Number of subjects: 146
Study 2865177 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of antichlamydial antibodies
Number of subjects: 146
Study 2865177 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of adnexal mass
Number of subjects: 146
Study 2865177 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of intrauterine contraceptive device (IUD)
Number of subjects: 146
Study 30388181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training frequency 1 time per week (F1)
Number of subjects: 36
Study 30388181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training frequency 2 times per week (F2)
Number of subjects: 36
Study 30388181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training frequency 3 times per week (F3)
Number of subjects: 36
Study 26943343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 61
Study 26943343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24810262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 737
Study 24810262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study 20840194 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted HDL (rHDL) infusion
Number of subjects: 29
Study 20840194 — intervention group
Group type: COMPARATOR
Intervention: Albumin infusion (Control)
Number of subjects: 29
Study 19845707 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft consisting of anorganic bovine bone (ABB) + autologous bone (AB)
Number of subjects: 90
Study 19845707 — intervention group
Group type: COMPARATOR
Intervention: Control pristine bone biopsies
Number of subjects: 90
Study 18479177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lornoxicam (Xefo, 2 mL, 8 mg) with normal saline 20 mL wound infiltration
Number of subjects: 60
Study 16197446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cytarabine (Ara‐C) and idarubicin (FLAI)
Number of subjects: 112
Study 16197446 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin plus Ara‐C and etoposide (ICE)
Number of subjects: 112
Study 12629090 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist triptorelin (GnRHa)
Number of subjects: 48
Study 12629090 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist triptorelin (GnRHa) plus calcium supplementation
Number of subjects: 48
Study 11051935 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Care Manual of the Perinatal Education Programme (PEP)
Number of subjects: 93
Study 11051935 — intervention group
Group type: COMPARATOR
Intervention: Control towns (no intervention)
Number of subjects: 93
Study 8724940 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation with a weak (1 microTesla) complex magnetic field applied over the left hemisphere, the right hemisphere, or bilaterally.
Number of subjects: 35
Study 8724940 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no magnetic field exposure).
Number of subjects: 35
Study 2004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose cyclosporin A therapy for 6 days with each course of anti-CEA (3 patients)
Number of subjects: 7
Study 2004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose cyclosporin A therapy (4 patients)
Number of subjects: 7
Study 2004846 — intervention group
Group type: COMPARATOR
Intervention: Without cyclosporin A
Number of subjects: 7
Study 2004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated therapy with 131I anti-CEA
Number of subjects: 7
Study 2004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir platelet count
Number of subjects: 7
Study 2004846 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion of the study
Number of subjects: 7
Study 7041297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 90
Study 7041297 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-aminoglycoside
Number of subjects: 90
Study 31711327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neural monitoring (IONM) during axillary dissection
Number of subjects: 22
Study 31711327 — intervention group
Group type: COMPARATOR
Intervention: Cautious nerve dissection (CND)
Number of subjects: 22
Study 31711327 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 22
Study 30993615 — intervention group
Group type: EXPERIMENTAL
Intervention: Group decision-making in grading committees
Number of subjects: 17
Study 30203768 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupleurum compound medicine
Number of subjects: 0
Study 30203768 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study 27339607 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (EB) diet (12105 kJ)
Number of subjects: 8
Study 27339607 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) diet (3039 kJ)
Number of subjects: 8
Study 27339607 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) diet
Number of subjects: 8
Study 27339607 — intervention group
Group type: COMPARATOR
Intervention: Energy balance (EB) diet
Number of subjects: 8
Study 24975853 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated Roux-en-Y (IsoRY)
Number of subjects: 153
Study 24975853 — intervention group
Group type: COMPARATOR
Intervention: Conventional reconstruction (CR)
Number of subjects: 153
Study 22545249 — intervention group
Group type: EXPERIMENTAL
Intervention: C-RPDs
Number of subjects: 54
Study 22545249 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-RPDs
Number of subjects: 54
Study 22545249 — intervention group
Group type: COMPARATOR
Intervention: C-RPDs and EP-RPDs
Number of subjects: 54
Study 19931204 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks PEG-IFN alpha and ribavirin treatment
Number of subjects: 807
Study 19931204 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks PEG-IFN alpha and ribavirin treatment
Number of subjects: 807
Study 19097962 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 30
Study 19097962 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane inhalation
Number of subjects: 30
Study 16274750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 425
Study 16274750 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 425
Study 12042551 — intervention group
Group type: EXPERIMENTAL
Intervention: Face covered by bedclothes during REM sleep
Number of subjects: 20
Study 12042551 — intervention group
Group type: EXPERIMENTAL
Intervention: Face covered by bedclothes during NREM sleep
Number of subjects: 20
Study 12042551 — intervention group
Group type: EXPERIMENTAL
Intervention: Face covered by bedclothes
Number of subjects: 20
Study 10442208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine/naloxone liquid formulation (50 mg/4 mg)
Number of subjects: 12
Study 10442208 — intervention group
Group type: COMPARATOR
Intervention: Ethanol-containing reference preparation (50 mg/4 mg)
Number of subjects: 12
Study 7880100 — intervention group
Group type: EXPERIMENTAL
Intervention: Navelbine
Number of subjects: 0
Study 7880100 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol in combination with cisplatin
Number of subjects: 0
Study 7880100 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11
Number of subjects: 0
Study 7880100 — intervention group
Group type: COMPARATOR
Intervention: Best conventional treatment
Number of subjects: 0
Study 2720017 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine (60 mg)
Number of subjects: 24
Study 2720017 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30122355 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Number of subjects: 54
Study 30122355 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transhepatic biliary drainage
Number of subjects: 54
Study 28654492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based task-oriented intervention at school by a school assistant or physical therapist
Number of subjects: 93
Study 28654492 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based task-oriented intervention in a health clinic by a physical therapist
Number of subjects: 93
Study 25705032 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight intervention
Number of subjects: 0
Study 25705032 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity intervention
Number of subjects: 0
Study 23327617 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic reasoning group
Number of subjects: 145
Study 23327617 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 145
Study 22093888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) group; infusion of 0.4 µg×kg(‐1)×h(‐1) for 10 min, adjusted between 0.2 and 0.4 µg×kg(‐1)×h(‐1) to maintain BIS around 80.
Number of subjects: 30
Study 22093888 — intervention group
Group type: COMPARATOR
Intervention: Control group; equivalent volume of normal saline administered.
Number of subjects: 30
Study 18303127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg qd
Number of subjects: 0
Study 18303127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Number of subjects: 0
Study 18303127 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel alone (control)
Number of subjects: 0
Study 18303127 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 0
Study 16464383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous ketamine analgesia (PCIKA) with intravenous small dose ketamine (20 g/L + droperidol 50 mg/L)
Number of subjects: 45
Study 16464383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous ketamine and fentanyl analgesia (PCIKFA) with intravenous small dose ketamine (10 g/L + fentanyl 5 mg/L + droperidol 50 mg/L)
Number of subjects: 45
Study 16464383 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia therapy (group CAT) with intramuscular injection of pethidine 50 mg and phenergan 25 mg
Number of subjects: 45
Study 12749433 — intervention group
Group type: EXPERIMENTAL
Intervention: TGZ-600 (600 mg/day)
Number of subjects: 305
Study 12749433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 305
Study 12749433 — intervention group
Group type: EXPERIMENTAL
Intervention: TGZ-150 (150 mg/day)
Number of subjects: 305
Study 12749433 — intervention group
Group type: EXPERIMENTAL
Intervention: TGZ-300 (300 mg/day)
Number of subjects: 305
Study 11055149 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hr exposure to low-intensity noise
Number of subjects: 40
Study 11055149 — intervention group
Group type: COMPARATOR
Intervention: Control condition (quiet)
Number of subjects: 40
Study 8822042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing session (three 10 min. stays at 85-95 degrees, relative humidity 25-30%)
Number of subjects: 7
Study 8822042 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 7
Study 1578921 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen with both early and late intensification
Number of subjects: 1614
Study 1578921 — intervention group
Group type: COMPARATOR
Intervention: Standard induction without intensification
Number of subjects: 1614
Study 2420153 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation plus bleomycin
Number of subjects: 46
Study 2420153 — intervention group
Group type: COMPARATOR
Intervention: Irradiation
Number of subjects: 46
Study 30076437 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic lumbar discectomy (PELD)
Number of subjects: 40
Study 30076437 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical laminotomy (ML)
Number of subjects: 40
Study 29908178 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-spectrum endoscopy (FUSE)
Number of subjects: 345
Study 29908178 — intervention group
Group type: COMPARATOR
Intervention: Standard forward-viewing colonoscopy (SFVC)
Number of subjects: 345
Study 26926750 — intervention group
Group type: EXPERIMENTAL
Intervention: Eagle Tactical Athlete Program (ETAP)
Number of subjects: 1720
Study 26926750 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 1720
Study 24708038 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy (exercises in lying position, 'open chain' exercises, isolated movements of extremities with trunk stabilization)
Number of subjects: 51
Study 24708038 — intervention group
Group type: COMPARATOR
Intervention: New physiotherapy (exercises in vertical position, sitting or standing, 'closed chain' exercises involving whole paretic side of the body)
Number of subjects: 51
Study 22665264 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 10 mg
Number of subjects: 15
Study 22665264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated rSo(2) (area under the curve) for rSo(2) ≤ 45%
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Average rSo(2) during the 60-minute period after cardiopulmonary bypass
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum rSo(2) during the 60-minute period after cardiopulmonary bypass
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Average rSo(2) from postinduction to 60 minutes post cardiopulmonary bypass
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Average rSo(2) during the rewarming phase
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Average rSo(2) during the 60-minute period following cardiopulmonary bypass
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor Development Index score
Number of subjects: 104
Study 20606124 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain hemosiderin
Number of subjects: 104
Study 19021804 — intervention group
Group type: EXPERIMENTAL
Intervention: winged beans
Number of subjects: 19
Study 19021804 — intervention group
Group type: EXPERIMENTAL
Intervention: ivy gourd
Number of subjects: 19
Study 19021804 — intervention group
Group type: COMPARATOR
Intervention: milk
Number of subjects: 19
Study 16041153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10-20 mg/day
Number of subjects: 361
Study 16041153 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 361
Study 12020958 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone-treated elderly men
Number of subjects: 0
Study 12020958 — intervention group
Group type: EXPERIMENTAL
Intervention: Young controls
Number of subjects: 0
Study 12020958 — intervention group
Group type: COMPARATOR
Intervention: Untreated elderly men
Number of subjects: 0
Study 10443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection to thyroarytenoid muscles only
Number of subjects: 5
Study 10443837 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection to both thyroarytenoid muscles and strap muscles
Number of subjects: 5
Study 10443837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated)
Number of subjects: 5
Study 7576396 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion
Number of subjects: 8
Study 7576396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2148176 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 12
Study 2148176 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 12
Study 2148176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2148176 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg and 20 mg
Number of subjects: 12
Study 88194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate
Number of subjects: 0
Study 88194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine sulfate
Number of subjects: 0
Study 88194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azatadine and pseudoephedrine
Number of subjects: 0
Study 29907999 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed Cheating (n = 107)
Number of subjects: 433
Study 29907999 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Initiated Cheating (n = 142)
Number of subjects: 433
Study 29907999 — intervention group
Group type: COMPARATOR
Intervention: Control (no explicit instructions to cheat)
Number of subjects: 433
Study 30783814 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 319